Risk factors for death rattle in terminally ill cancer patients: a prospective exploratory study

Abstract

Death rattle is frequently observed in cancer patients whose death is impending and may contribute to the severe distress of patients and their family members. To identify risk factors for development and persistency of death rattle, a prospective study was performed on 245 hospice inpatients.

One-hundred-and-seven patients (44%) developed death rattle, 71% of whom achieved satisfactory symptom palliation until death. A multiple regression analysis identified neoplasms of brain and lung as independent risk factors for development of death rattle, while refractory symptoms were significantly associated with pulmonary neoplasms and infection/oedema.

In conclusion, development of death rattle was influenced by both brain and lung malignancies, while its persistency was mainly determined by pulmonary pathology. A clinical classification of death rattle based on these factors would be established by a further confirmatory study.

Keywords

death rattle neoplasms terminal care

Get full access to this article

View all access options for this article.

References

Ellershaw JE , Sutcliffe JM , Saunders CM . Dehydration and the dying patient. J Pain Symptom Manage 1995; 10: 192–197.

Hughes AC , Wilcock A , Corcoran R . Management of ‘death rattle’. J Pain Symptom Manage 1996; 12: 271–272.

Bennett MI . Death rattle: an audit of hyoscine (scopolamine) use and review of management. J Pain Symptom Manage 1996; 12: 229–233.

Twycross RG , Lichter I . The terminal phase. Death rattle. In: Doyle D , Hanks GCW , MacDonald N eds. Oxford textbook of palliative medicine, 2nd edn. New York: Oxford Medical Publications, 1998: 985–986.

Anderson F , Downing GM , Hill J . Palliative Performance Scale (PPS): a new tool. J Palliat Care 1996; 12: 5–11.

Riker R , Fraser GL , Cox PM . Continuous infusion of haloperidol controls agitation in clinically ill patients. Crit Care Med 1994; 22: 433–440.

Lichter I , Hunt E . The last 48 hours of life. J Palliat Care 1990; 6: 7–15.

Morita T , Tsunoda J , Inoue S et al. Contributing factors to physical symptoms in terminally ill cancer patients. J Pain Symptom Manage 1999; in press.

Power D , Kearney M . Management of the final 24 hours. Ir Med J 1992; 85: 93–95.

10.

Bausewein C , Twycross R . Comparative cost of hyoscine injections. Palliat Med 1995; 9: 256.

11.

Spruyt O , Kausae A . Antibiotic use for infective terminal respiratory secretions. J Pain Symptom Manage 1998 15: 263–264.